Cargando…
Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy
Uveal melanoma is the most common primary intraocular malignancy. The aim of this retrospective study was to report the results after ruthenium-106 (Ru-106) plaque brachytherapy for uveal melanoma in terms of tumor control, visual acuity, radiation-related complications, tumor recurrence, metastases...
Autores principales: | Cennamo, Gilda, Montorio, Daniela, D’ Andrea, Luca, Farella, Antonio, Matano, Elide, Giuliano, Mario, Liuzzi, Raffaele, Breve, Maria Angelica, De Placido, Sabino, Cennamo, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763327/ https://www.ncbi.nlm.nih.gov/pubmed/35047387 http://dx.doi.org/10.3389/fonc.2021.754108 |
Ejemplares similares
-
Retinal Vascular Changes in Radiation Maculopathy after Intravitreal Ranibizumab by Optical Coherence Tomography Angiography
por: Cennamo, Gilda, et al.
Publicado: (2020) -
Brachytherapy of Uveal Melanomas with Ruthenium-106 Plaques
por: Belaïd, Asma, et al.
Publicado: (2016) -
(106)Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma
por: Jiang, Ping, et al.
Publicado: (2020) -
Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma
por: Tagliaferri, Luca, et al.
Publicado: (2017) -
Evaluation of optic nerve subarachnoid space in primary open angle glaucoma using ultrasound examination
por: Cennamo, Gilda, et al.
Publicado: (2018)